Lenalidomide,Idecabtagene vicleucel
bms,2seventy bio
['equate', 'multiple myeloma', 'ide-cel', 'nct03601078', 'karmma', 'karmma-2', '3314']
congress l #ash22 provides an update from the karmma-2 trial cohort 2a, on the efficacy and safety of ide-cel for clinical high-risk mm, with 37 patients treated after early relapse. at median follow-up of 21.5 months, crr=45.9% and orr =83.8% 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma